Increasing vulnerability to infections with Y. pseudotuberculosis can result in substantial harm, especially among children and immunocompromised individuals. By harnessing the latest scientific advancements and employing rigorous preclinical research methodologies, we are committed to advancing the frontier of Y. pseudotuberculosis infection vaccines and therapies.
Introduction to Yersinia Pseudotuberculosis Infection
Yersinia pseudotuberculosis is pathogenic bacterium from the Yersinia genus which also harbours Yersinia pestis, the causal organism of plague. Y. pseudotuberculosis mostly causes intestinal infections and is responsible for yersiniosis in humans. This pathogen is mostly spread via contaminated water or food and may result in fever, pain, and diarrheoa. The major concern of the infection is its ability to affect a number of animal reservoirs including rodents, giving it zoonotic potential.
Fig.1 Colonization patterns of Y. pseudotuberculosis during acute and persistent infection. (Heine W., et al., 2018)
Vaccine Development for Yersinia Pseudotuberculosis Infection
- Live Attenuated Vaccines
Efforts against Y. pseudotuberculosis have advanced with the development of live attenuated vaccines which are some of the most sophisticated classes of self-replicating but nonpathogenic bacteria. An excellent case is the murine model, in which VTnF1 strain has been shown to be a successful vaccine for both plague and yersiniosis.
- Subunit and Recombinant Vaccines
Subuit and recombinant vaccines are directed towards certain antigens of y. pseudotuberculosis, for instance, the immunogens. F1-V vaccine is particularly interesting since it uses the F1 capsular protein and the LTCRV antigen together with Y. pestis. This is useful in the context of strategies against plague. Such vaccines are, however, favorable since their composition is more limited and the probability of reverting to a virulent form is small.
Therapeutics Development for Yersinia Pseudotuberculosis Infection
Monoclonal Antibodies
These can be designed to target specific toxin markers or enhance the immune system's ability to target a certain pathogenic organism.
Antibiotic Therapy
With regards to the commonplace antibiotics and their respective prescriptions, aminoglycosides, trospecte tetracyclines, and fluoroquinolones rank among the most frequent ones.
Immunotherapy
This is so because there are those who have still not combined these techniques and are looking for more targeted methods like these with stronger antibodies, and immune checkpoint inhibitors.
Our Services
Here at our company, we are devoted to the development of vaccines and therapeutics against Yersinia pseudotuberculosis infections. These are highly complex tasks but our multidisciplinary team is able to appreciate the employment of advanced technologies and systems into the end result.
Disease Models
- Oral Gavage Models
- Bread-Feeding Models: The bacterial culture is resuspended in melted butter and soaked into small pieces of white bread.
We offer comprehensive services that encompass vaccine formulation, and preclinical research. Our focus on collaboration ensures that we work closely with stakeholders to translate scientific discoveries into effective interventions. If you are interested in our services, please feel free to contact us.
References
- Heine, Wiebke, et al. "Loss of CNFY toxin-induced inflammation drives Yersinia pseudotuberculosis into persistency." PLoS pathogens 14.2 (2018): e1006858.
- Singh, Amit K., Roy Curtiss III, and Wei Sun. "A recombinant attenuated Yersinia pseudotuberculosis vaccine delivering a Y. pestis YopENt138-LcrV fusion elicits broad protection against plague and yersiniosis in mice." Infection and Immunity 87.10 (2019): 10-1128.
- Kimura, Jiro, and Kiyoshi Sasaki. "Yersinia pseudotuberculosis infection intractable by antibiotics: A rare case report." International Journal of Surgery Case Reports 21 (2016): 139-141.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
